ICON8B: A trial of chemotherapy and bevacizumab in ovarian cancer

Trial at a glance

Closed trial

  • Cancer type: Epithelial – high-grade serous and endometrioid
  • Treatment stage: Primary treatment
  • Acronym: ICON8B

ICON8B: A trial looking at chemotherapy weekly with bevacizumab versus three weekly with bevacizumab for advanced ovarian cancer

Who can take part

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.


You may be able to take part in this clinical trial if you:

  • epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer 
  • a cancer that is staged as high risk
  • good overall levels of fitness and satisfactory blood test results

This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.

About the trial

The study aims to find out the answers to the following questions:

  • Is one of these treatment approaches better than the other?
  • Which treatment causes fewer side effects?
  • Which treatment offers a better quality of life?
  • Is it safe to use bevacizumab to treat women who are having surgery at the same time as chemotherapy?

If you take part in this study, you'll be randomised (placed into a treatment group by a computer) into one of two treatment groups:

  • Group B1 – you'll receive chemotherapy and bevacizumab at weekly intervals. Participants in this group will receive 18 weeks of:
    • carboplatin once every three weeks
    • paclitaxel once every three weeks
    • bevacizumab once every three weeks followed by bevacizumab continuing alone for approximately 11 months
  • Group B3 – you'll receive chemotherapy and bevacizumab at three weekly intervals. Participants in this group will receive 18 weeks of:
    • carboplatin once every three weeks
    • paclitaxel once every week (on days one, eight and 15 of a three-weekly cycle)
    • bevacizumab once every three weeks followed by bevacizumab continuing alone for approximately 11 months